A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa

Key facts

Sponsor

Ocugen

Principal Investigator

Huma Qamar

Ocugen

Intervention

Sub-Retinal Administration of OCU400-301(genetic)

Enrollment

140 enrolled

Eligibility

3 years · All sexes

Timeline

2024 – 2027

Study locations (17)

• Associated Retina Consultants, Phoenix, Arizona, United States
• University of Southern Califormia, La Jolla, California, United States
• University of Southern California, Roski Eye Insitute, Los Angeles, California, United States
• Advanced Research, LLC., Deerfield Beach, Florida, United States
• Bascom Palmer Eye Institute, University of Miami, Miller School of Medicine, Miami, Florida, United States
• Erie Retina Research LLC, Erie, Pennsylvania, United States
• Vanderbilt Eye Institute, Nashville, Tennessee, United States
• Retina Consultants of Texas, Bellaire, Texas, United States
• Retina Foundation of the Southwest, Dallas, Texas, United States
• Baylor College of Medicine, Houston, Texas, United States
• Valley Retina Institute, McAllen, Texas, United States
• Gundersen Health System, La Crosse, Wisconsin, United States
• Calgary Retina Consultants, Calgary, Alberta, Canada
• University of Alberta, Edmonton, Alberta, Canada
• The University of British Columbia, Vancouver, British Columbia, Canada
• +2 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for OBSOLETE: Inherited retinal disorder

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1, PHASE2NCT07408232
  A Phase 1/2 Study in Healthy Volunteers and Participants With Autosomal Dominant Retinitis Pigmentosa (RHO-adRP)
  Octant, Inc.
• RECRUITINGEARLY PHASE1NCT07063030
  A Study of LX107 Gene Therapy in AIPL1-IRD Patients
  Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
• RECRUITINGPHASE1, PHASE2NCT06852963
  A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001
  PYC Therapeutics
• RECRUITINGPHASE1NCT06319872
  The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration
  University of Rochester
• RECRUITINGPHASE1NCT06936787
  An Open-label, Dose-ascending Study of IGT001 for Retinitis Pigmentosa
  Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
• ENROLLING BY INVITATIONNCT07056738
  Prospective Exploratory Cohort Study on Ganglion Cell Degeneration in Retinitis Pigmentosa Patients
  University Medical Center Goettingen
• RECRUITINGPHASE1NCT06455826
  MAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects (Wallaby)
  PYC Therapeutics
• RECRUITINGEARLY PHASE1NCT06292650
  Safety and Efficacy Study of Novel Gene Therapy ZM-02 for Retinitis Pigmentosa Patients
  Zhongmou Therapeutics

See all trials for OBSOLETE: Inherited retinal disorder →